Terms: = Kidney tumors AND JAK2, ENSG00000096968, O60674, JTK10, 3717 AND Treatment
27 results:
1. Enhanced synergy of pacritinib with temsirolimus and sunitinib in preclinical renal cell carcinoma model by targeting jak2/STAT pathway.
Mao F; Gao L; Liu L; Tang Y
J Chemother; 2024 May; 36(3):238-248. PubMed ID: 37916436
[TBL] [Abstract] [Full Text] [Related]
2. Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives.
Krecak I; Verstovsek S; Lucijanic M
Ann Hematol; 2024 May; 103(5):1513-1523. PubMed ID: 37665349
[TBL] [Abstract] [Full Text] [Related]
3. Gene mutation profiling and clinical significances in patients with renal cell carcinoma.
Wang Y; He P; Zhou X; Wang C; Fu J; Zhang D; Liao D; Zhou Z; Wu C; Gong W
Clinics (Sao Paulo); 2023; 78():100259. PubMed ID: 37515929
[TBL] [Abstract] [Full Text] [Related]
4. Resveratrol Loaded by Folate-Modified Liposomes Inhibits Osteosarcoma Growth and Lung Metastasis via Regulating jak2/STAT3 Pathway.
Zhu WT; Zeng XF; Yang H; Jia ML; Zhang W; Liu W; Liu SY
Int J Nanomedicine; 2023; 18():2677-2691. PubMed ID: 37228445
[TBL] [Abstract] [Full Text] [Related]
5. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Verstovsek S; Gerds AT; Vannucchi AM; Al-Ali HK; Lavie D; Kuykendall AT; Grosicki S; Iurlo A; Goh YT; Lazaroiu MC; Egyed M; Fox ML; McLornan D; Perkins A; Yoon SS; Gupta V; Kiladjian JJ; Granacher N; Lee SE; Ocroteala L; Passamonti F; Harrison CN; Klencke BJ; Ro S; Donahue R; Kawashima J; Mesa R;
Lancet; 2023 Jan; 401(10373):269-280. PubMed ID: 36709073
[TBL] [Abstract] [Full Text] [Related]
6. Anlotinib combined with the PD-L1 blockade exerts the potent anti-tumor immunity in renal cancer treatment.
Li J; Cao P; Chen Y; Wang J; Sun X; Chen R; Wang G; Hou J
Exp Cell Res; 2022 Aug; 417(1):113197. PubMed ID: 35568074
[TBL] [Abstract] [Full Text] [Related]
7. treatment of Essential Thrombocythemia with Anagrelide Is Associated with an Increased Risk of Worsened kidney Function.
Kwiatkowski J; Kuliszkiewicz-Janus M; Rymer W; Jaźwiec B; Małecki R
Pharmacology; 2021; 106(5-6):316-322. PubMed ID: 33691325
[TBL] [Abstract] [Full Text] [Related]
8. Mechanism of gypenosides of Gynostemma pentaphyllum inducing apoptosis of renal cell carcinoma by PI3K/AKT/mTOR pathway.
Liu H; Li X; Duan Y; Xie JB; Piao XL
J Ethnopharmacol; 2021 May; 271():113907. PubMed ID: 33556477
[TBL] [Abstract] [Full Text] [Related]
9. Nobiletin inhibits viability of human renal carcinoma cells via the jak2/STAT3 and PI3K/Akt pathway.
Xu Z; Wu D; Fu D; Tang C; Ge J; Zhang Z; Zhou W
Cell Mol Biol (Noisy-le-grand); 2020 Jul; 66(5):199-203. PubMed ID: 33040836
[TBL] [Abstract] [Full Text] [Related]
10. A Study on the Immunohistochemical Expressions of Leptin and Leptin Receptor in Clear Cell Renal Cell Carcinoma.
Perumal K; Mun KS; Yap NY; Razack AHA; Gobe GC; Ong TA; Kuppusamy S; Rajandram R
Biomed Res Int; 2020; 2020():3682086. PubMed ID: 32802842
[TBL] [Abstract] [Full Text] [Related]
11. Thymoquinone induces apoptosis of human renal carcinoma Caki-1 cells by inhibiting jak2/STAT3 through pro-oxidant effect.
Chae IG; Song NY; Kim DH; Lee MY; Park JM; Chun KS
Food Chem Toxicol; 2020 May; 139():111253. PubMed ID: 32165235
[TBL] [Abstract] [Full Text] [Related]
12. Novel Detection of CALR-Mutated Cells in Myeloproliferative Neoplasm-Related Glomerulopathy With Interstitial Extramedullary Hematopoiesis: A Case Report.
Maruyama K; Nakagawa N; Suzuki A; Kabara M; Matsuki M; Shindo M; Iwasaki S; Ogawa Y; Hasebe N
Am J Kidney Dis; 2019 Dec; 74(6):844-848. PubMed ID: 31377025
[TBL] [Abstract] [Full Text] [Related]
13. S-Adenosylmethionine synergistically enhances the antitumor effect of gemcitabine against pancreatic cancer through jak2/STAT3 pathway.
Liu Y; Bi T; Liu L; Gao Q; Shen G; Qin L
Naunyn Schmiedebergs Arch Pharmacol; 2019 May; 392(5):615-622. PubMed ID: 30683944
[TBL] [Abstract] [Full Text] [Related]
14. PBX1 promotes the cell proliferation via jak2/STAT3 signaling in clear cell renal carcinoma.
Wei X; Yu L; Li Y
Biochem Biophys Res Commun; 2018 Jun; 500(3):650-657. PubMed ID: 29678569
[TBL] [Abstract] [Full Text] [Related]
15. Isoliquiritigenin inhibits the proliferation of human renal carcinoma Caki cells through the ROS-mediated regulation of the jak2/STAT3 pathway.
Kim DH; Park JE; Chae IG; Park G; Lee S; Chun KS
Oncol Rep; 2017 Jul; 38(1):575-583. PubMed ID: 28560439
[TBL] [Abstract] [Full Text] [Related]
16. The IGF-I/jak2-STAT3/miR-21 signaling pathway may be associated with human renal cell carcinoma cell growth.
Su Y; Zhao A; Cheng G; Xu J; Ji E; Sun W
Cancer Biomark; 2017 Jul; 19(3):289-296. PubMed ID: 28453463
[TBL] [Abstract] [Full Text] [Related]
17. Aqueous Extracts of Toona sinensis Leaves Inhibit Renal Carcinoma Cell Growth and Migration Through jak2/stat3, Akt, MEK/ERK, and mTOR/HIF-2α Pathways.
Chen YC; Chien LH; Huang BM; Chia YC; Chiu HF
Nutr Cancer; 2016; 68(4):654-66. PubMed ID: 27115866
[TBL] [Abstract] [Full Text] [Related]
18. Microarray and Proteomic Analyses of Myeloproliferative Neoplasms with a Highlight on the mTOR Signaling Pathway.
Čokić VP; Mossuz P; Han J; Socoro N; Beleslin-Čokić BB; Mitrović O; Subotički T; Diklić M; Leković D; Gotić M; Puri RK; Noguchi CT; Schechter AN
PLoS One; 2015; 10(8):e0135463. PubMed ID: 26275051
[TBL] [Abstract] [Full Text] [Related]
19. Icaritin inhibits JAK/STAT3 signaling and growth of renal cell carcinoma.
Li S; Priceman SJ; Xin H; Zhang W; Deng J; Liu Y; Huang J; Zhu W; Chen M; Hu W; Deng X; Zhang J; Yu H; He G
PLoS One; 2013; 8(12):e81657. PubMed ID: 24324713
[TBL] [Abstract] [Full Text] [Related]
20. Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and jak2/STAT3 pathway.
Fang Z; Tang Y; Fang J; Zhou Z; Xing Z; Guo Z; Guo X; Wang W; Jiao W; Xu Z; Liu Z
PLoS One; 2013; 8(5):e62823. PubMed ID: 23690956
[TBL] [Abstract] [Full Text] [Related]
[Next]
